CL Educate Q2: Recovery picks up speed

After the FY21 year-end result of CL Educate, we wrote in June’21: In fact, when it looks back at FY21 many years later, it may find that it was a key turning point in its corporate journey. Then after Q1 FY22 results, we wrote in Aug’21: After 2 years –…

Read More

USD 3.3B of VC/PE investment in lifesciences firms in Sep’21

We recorded 79 VC/PE transactions pertaining to the global life sciences sector for September 2021, aggregating to a sum of USD 3.3B, as against 96 transactions and USD5.6B in Sep’20. The USA recorded 49 transactions aggregating to a total investment of USD 2.2B. China reported a totally out of character…

Read More

Sales Multiple Biryani or PE Biryani

The other day I was talking to a person who is an early-stage investor. He was looking to invest in a food business. He explained to me his criterion: he said his fund wanted to invest in a sales-multiple food business. This foxed me. I have heard of packaged food…

Read More

CL Educate heads into a positive cycle

After 2 years – FY20 and FY21 – of hanging tough, CL Educate appears to have entered a cycle of positive developments from FY22. Q1 FY22 results showed early indications of this. Firstly, there are signs of return to growth, despite Covid-2 wave still going strong in Q1 FY22. Stand…

Read More

USD 6.5B of VC/PE investment in lifesciences firms in June’21

We recorded 114 VC/PE transactions pertaining to the global life sciences sector for June 2021, aggregating to a sum of USD 6.47B. The USA recorded 69 transactions aggregating to a total investment of USD 3.26B. China reported investment of USD 886m from 11 VC/PE transactions. Rest of the world accounted…

Read More

CL Educate emerges healthier from FY21

FY21 didn’t turn out too bad for CL Educate. In fact, when it looks back at FY21 many years later, it may find that it was a key turning point in its corporate journey. That is not to say it was a rosy FY21 for CL. The global scourge Covid…

Read More

Chemcrux declares decent performance in FY21 despite plant closure

Chemcrux Enterprises suffered only a 7% revenue drop and 17% EBITDA drop in FY21, despite losing over 23% of productive days due to plant closure, and Covid related production constraints in FY21. Highlights of the FY21 results: FY21 full year sales came in at Rs 533m, 7% drop over sales…

Read More

USD 6.6B of VC/PE investment in lifesciences firms in May’21

We recorded 94 VC/PE transactions pertaining to the global life sciences sector for May 2021, aggregating to a sum of USD 6.56B. The USA recorded 60 transactions aggregating to a total investment of USD 3.3B. China reported investment of USD 1.8B from 12 VC/PE transactions. Rest of the world accounted…

Read More

USD 6.5B of VC/PE investment in lifesciences firms in Apr’21

We recorded 131 VC/PE transactions pertaining to the global life sciences sector for April 2021, aggregating to a sum of USD 6.5B. The USA recorded 88 transactions with total investment of USD 3.8B. China reported investment of USD 585m from 12 VC/PE transactions. Rest of world accounted for 31 transactions…

Read More

WISDOM IR CASE STUDY – CL EDUCATE LIMITED

Here’s a case study showing Wisdom IR’s research based approach to investor relations works.    

Read More